Home Cart Sign in  
Chemical Structure| 761423-87-4 Chemical Structure| 761423-87-4

Structure of Ipragliflozin
CAS No.: 761423-87-4

Chemical Structure| 761423-87-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ipragliflozin is a selective inhibitor of SGLT2 with IC50 of 14 nM for hSGLT2.

Synonyms: ASP1941

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ipragliflozin

CAS No. :761423-87-4
Formula : C21H21FO5S
M.W : 404.45
SMILES Code : O[C@H]1[C@H](C2=CC=C(F)C(CC3=CC4=CC=CC=C4S3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Synonyms :
ASP1941
MDL No. :MFCD19443744

Safety of Ipragliflozin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Ipragliflozin (ASP1941) is an orally active and selective inhibitor of SGLT2, with IC50s of 7.38 and 1876 nM for human SGLT2 and SGLT1, respectively. It serves as an antidiabetic agent[1].
Target
  • SGLT2

    hSGLT2, IC50:7.4 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01972880 Healthy|Plasma Concentration o... More >>f ASP1941 Less << PHASE1 COMPLETED 2025-01-14 Kyushu, Japan
NCT01302028 Type 2 Diabetes Mellitus PHASE1 COMPLETED 2010-06-26 Brno, 62500, Czechia|Prague, 1... More >>6900, Czechia|Balatonfured, 8230, Hungary|Warsaw, 02-097, Poland|Bratislava, 83305, Slovakia Less <<
NCT01097681 Type 2 Diabetes Mellitus PHASE1 COMPLETED 2010-06-18 Kansai, Japan|Kantou, Japan
NCT02291874 Type 2 Diabetes Mellitus PHASE4 COMPLETED 2016-07-07 Chubu, Japan|Chugoku, Japan|Ho... More >>kkaido, Japan|Kansai, Japan|Kanto, Japan|Kyushu, Japan Less <<
NCT01611428 Bioavailability of Ipraglifloz... More >>in|Healthy Subjects Less << PHASE1 COMPLETED 2025-07-11 Leeds, LS2 9LH, United Kingdom
NCT01187186 Liver Disease PHASE1 COMPLETED 2025-08-10 Miami, Florida, 33014, United ... More >>States Less <<
NCT01674777 Healthy|Pharmacokinetics of AS... More >>P1941 Less << PHASE1 COMPLETED 2025-12-10 Kantou, Japan
NCT01302132 Healthy Subjects PHASE1 COMPLETED 2025-10-08 Zuidlaren, 9470 AE, Netherland... More >>s Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.36mL

2.47mL

1.24mL

24.72mL

4.94mL

2.47mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories